BioSpace News Archive

Medigene AG announced that the Company has been issued a patent by the European Patent Office protecting its inducible Medigene T cell receptor technology, which contains a control mechanism to regulate efficacy and improve safety of its T cell receptor engineered T cell therapies.

Achilles Therapeutics plc announced interim Phase I/IIa data on the use of clonal neoantigen reactive T cells from the CHIRON study in advanced unresectable or metastatic non-small cell lung cancer and the THETIS study in recurrent or metastatic malignant melanoma.

Haemonetics Corporation, a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, announced that it has received 510 clearance from the U.S. Food and Drug Administration for the TEG® 6s hemostasis analyzer system Global Hemostasis-HN assay cartridge.

Achilles Therapeutics plc announced its financial results for the fourth quarter and year-ended December 31, 2023, and recent business highlights.

Pharvaris announced the acceptance of two abstracts for presentation at the Consortium of Independent Immunology Clinics Spring 2024 Conference, to be held from April 12-13, 2024, in Arlington, TX.

CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived recombinant human collagen (rhCollagen) for tissue regeneration and organ manufacturing, today announced financial results for the full year ended December 31, 2023 and provided a corporate update.

MiNA Therapeutics today announced a research collaboration and licensing agreement option with Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; Headquarters: Kyoto; President: Toru Nakai), an innovation-driven Japanese-based pharmaceutical company focused on disease areas of high unmet medical need.

Odyssey Therapeutics, Inc. announced today it has entered into a strategic research collaboration with Janssen Pharmaceutica NV, a Johnson & Johnson company, to jointly discover and ooptimize small molecule medicines against select therapeutic targets.

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced the Company has started a process with the U.S. Food and Drug Administration (FDA) and Health Canada to voluntarily discontinue the marketing authorizations for RELYVRIO®/ALBRIOZA™.

SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the “Company”) today announced Samuel J. Reich, the company’s Chairman and CEO, will present an overview of the company at the upcoming 23rd Annual Needham Virtual Conference on Thursday, April 11, 2024 at 1:30 p.m. ET.